.
Mastalgia or mastodynia are a frequent complaint in general practice (Preece et al., 1976; Fentiman et al., 1986) .
Their cumulated incidence rate in women has been estimated by some authors (Kallner, 1985; Maddox et al., 1989) to be as high as 45% during the genital life. They are sometimes considered as part of fibrocystic disease (Sitruk-Ware et al., 1977; Vorherr et al., 1986) , although their evidence and somatic relevance are frequently denied (Love et al., 1982; Dupont & Page, 1985) .
Several characteristics of mastalgia seem to establish a relation between their occurrence and breast oestrogen impact, namely its bilaterality and periodicity in relation with the menstrual phases, its disappearance after surgical or chemical castration or after anti-oestrogen therapy like progestins or tamoxifen, its possible exacerbation or occurrence under oestrogen or oral contraceptive use.
Hormonal risk factors for breast cancers have been extensively studied in the past 20 years (MacMahon et al., 1973; Kelsey, 1979; Korenman, 1980; Cowan et al., 1981; Henderson et al., 1982; Kelsey & Berkowitz, 1988; Krieger, 1989) . Several authors (MacPherson et al., 1987a; Muir, 1990) have already pointed out the long delay between the emergence of the first cancerous clone and the breast cancer diagnosis and much effort has been put on the characterisation of high risk populations, and on the delineation of more susceptible periods like the period starting at menarche and ending at first full term pregnancy (FFTP).
More recently, Leinster et al. (1987) showed a higher incidence of high risk mammographic patterns in women with cyclical mastalgia and speculated about a possible link with later occurrence of breast cancer.
To investigate the role of cyclical mastalgia as a potential precocious marker of breast steroid susceptibility in relation (Pike et al., 1983; Cancer and Steroid Hormone Study (CASH), 1986; MacPherson et al., 1987b; Miller et al., 1989; Olsson et al., 1989; Stadel et al., 1989; UK National Case-Control Study Group, 1989; Clavel et al., 1991 Oral contraceptive uses were elicited by constructing a monthly calendar of events starting at menarche up to the time of the interview. Contraceptive use was associated with marking events like first sexual intercourse, marriage, FFTP. Information on brand names used was elicited with the aid of good colour prints of the packaging, showing its front and back and its content. Oral contraceptives used by the patients of this study were recorded according to the three following categories; (1) standard dose oral contraceptives (SDC) containing 50 micrograms (JLg) per pill of ethynil-estradiol (EE); (2) Low oral dose contraceptives (LDC) containing less than 40 g per pill of EE; (3) continuous microprogestative pill (P). However, the limited number of patients exposed to the two last categories did not allow us to take into account this variable and only global results are presented.
Definition of cyclical mastalgia As the concept of mastalgia is rather controversial, we adopted very stringent criteria and interviewers were more particularly trained in this regard. Details of the questions can be found in appendix. Cyclical mastalgia (CM) was defined as a bilateral painful breast swelling, lasting for more than 4 days and up to 3 weeks, always preceding menses and subsiding during menstruation. This monthly event was noted only if it persisted for more than 6 months. This definition clearly discarded non cyclical mastalgia and Tietze's disease and is in accordance with classification proposed by previous authors (Preece et al., 1976; Wisbey et al., 1983) . This symptom was recorded separately for various phases of genital life, i.e. during the period starting at menarche until FFTP, and after FFTP if the interviewee had already been pregnant, otherwise until the time of the interview. For each type of OC used were recorded the age at first use, the total duration of use, and, when it was relevant, the existence, exact chronology and duration of breast pain and swelling.
Statistical analysis
Comparisons between groups were performed using the student's t-test for paired and unpaired quantitative data and chi square test for qualitative data.
We used the multivariate logistic regression methods for matched case-control studies (Breslow & Day, 1978) .
The strategy of performing a 1:1 analysis exposed us to overmatching as about 20% of cases could be associated with the same control. Following the recommendations of several authors (Breslow & Day, 1980; Brookmeyer et al., 1986) , we initially performed a general matched analysis with unequal strata and unequal cases and controls within each stratum using a modified version of the Breslow and Day program (Thalabard et al., 1989 (months) (n = 162) (n = 143) The number n in brackets indicates the number of subjects exposed to the factor. Last column: P-value (two-tailed situation). N.S. corresponds to P>0.05. (Anderson et al., 1977; Dupont & Page, 1985; Wang & Fentiman, 1985; Kelsey & Berkowitz, 1988; Dupont et al., 1989) . The magnitude of the observed effects seems to be in agreement with data reported by these authors. Initial cohort studies in the seventies and early eighties could not find any increase in BC occurrence in oral contraceptive users (Trapido, 1981; Kay & Hannaford, 1988; Vessey et al., 1989; Romieu et al., 1989) . More recently, several authors have brought evidence suggesting a potential association between long term oral contraceptive use before FFTP and later occurrence of BC (Paffenberger et al., 1980; Pike et al., 1981; Meirick et al., 1986; MacPherson et al., 1987b; Stadel et al., 1989) , although these results have been and are still widely debated (Schlesselman, 1989; Chilvers & Deacon, 1990) . Our data are consistent with those findings as we could detect a significant increase of the RR in long term OC users and this tendency was found as well, though attenuated, in long term users before FFTP and, to a lesser extent, in long term users after FFTP. We could not analyse further on the specific effect of LOC and progestin only pill due to insufficient data for exclusive users of those specific OC types. It is noteworthy that the matching design exposed both cases and controls to the same type of OC compounds despite the profound changes in OC composition between the sixties and the eighties.
Cyclical mastalgia as defined in our study was found significantly associated with breast cancer, even after adjustment for the previously mentioned potential confounding factors.
This result is rather astonishing and must be interpreted with caution considering the subjectivity of this symptom. The limits of case-control studies have been already largely addressed (Skegg, 1988) and could account entirely for the observed results thus forbiding any generalisation. A possibility of a selection and a recall bias has to be discussed. A recall bias could account for these results: in their attempt to give a rational to the origin of their disease, women diagnosed with BC are thought to be more likely to report breast events than normal women (Skegg et al., 1988 A selection bias can be minimised on the following arguments: first, the restriction of our control group to patients exposed to the same environment, with a matching on year of birth, age at interview, educational level, age at FFTP, when possible, should have limited major environmental factors and birth cohort effect (Lund, 1989) ; second, as personal history of BBD is known to increase the risk of BC, a higher number of patients with previous history of BBD among the cases could account for the effect of cyclical mastalgia. However, we still observed the effect of cyclical mastalgia after adjustment on BBD and no significant interaction between this factor and BBD could be found.
The statistical analysis was carried out on a 1:1 matched basis thus ensuing equal strata and facilitating analysis. Overmatching was ruled out by our comparison with the global analysis and the simulated study.
Experimental and human data associate breast swelling and pain with exposure to oestrogens. Wisbey et al. (1983) noticed that cyclical pain usually begins early in genital life, before the end of the third decade of age and persists for a long time, sometimes resuming at a time of a major hormonal change like pregnancy, but frequently ending only at the onset of the menopause, suggesting its association with individual hormonal secretion characteristics. However it is a clinical evidence in reproductive endocrinology that plasma oestradiol levels do not totally reflect the hormonal impact at the target level. The large inter-and intra-individual variability in the amount of drugs necessary to achieved the same effect at the target level (induction of the LH pulse when monitoring the menstrual cycle; relief of post castration or post menopausal symptoms in oestrogen replacement therapies) could explain the difficulties of studies aiming to demonstrate an excess in oestrogen plasma level, in women with BC (Wysowski et al., 1987; Krieger, 1989) . Boyd et al. (1988) have shown an association between the fat intake, the cholesterol plasma level, which is a precursor of the sexual hormones, and the severity of the symptom. Other authors have suggested the involvement of prolactin (Watt-Boolson, 1981) or progesterone (Pike et al., 1983) , but always pointing out to an hypersensitivity to the oestrogen environment. In our definition cyclical mastalgia is an easy and early marker of breast susceptibility to oestrogen. The present study suggest its predictive value in addition to other classical risk factors of BC. We hope that future cohort studies will include and record accurately this symptom to prove its pertinency. -Do (did) you experience this symptom continuously for more than 6 months? When and how it has disappeared?
